Exelixis' Zanzalintinib Catalysts Firm Up for 1H 2027, But Thesis Unchanged at WAIT

What happened

Exelixis remains a story of Cabometyx-driven cash flow with investors turning attention to zanzalintinib's regulatory milestones, as highlighted in a Nov. 13 Motley Fool piece pointing to two catalysts by March 2027—likely the FDA decision on the metastatic colorectal cancer NDA and top-line STELLAR-304 data in non-clear-cell RCC. The company's existing franchise grew revenues to $1.8B in 2024 and guided to $2.325-2.425B net product revenue for 2026, sustaining profitability but leaving the stock at roughly 17x EPS and 16x EBITDA, with single-product concentration and a 2026-2033 patent cliff as structural overhangs. The zanzalintinib program has progressed through positive Phase 3 STELLAR-303 data and a planned NDA submission, but the article adds no new clinical or regulatory information beyond confirming the timeline, which appears slightly later than management's earlier 2025 submission plan. With the stock already up ~28% over twelve months and institutions selling into strength per low accumulation ratings, the event path is well anticipated and crowded. No fundamental change has occurred; the setup still favors patience over chasing binary catalysts.

Implication

The binary nature of the upcoming catalysts limits the benefit of holding through the events at current prices; a pullback toward $38 would restore a more favorable risk-reward. Investors should treat the FDA decision and STELLAR-304 outcome as confirmatory rather than transformative, as even clean approval adds only option value to a franchise still dominated by Cabometyx. The core value driver remains whether Cabometyx can sustain ~45% RCC TKI share and double-digit volume growth; two consecutive quarters of share below 40% or net pricing degradation would undercut the base case. If the stock rises above $52 on any positive data, trimming into strength is prudent given limited upside to the $55 bull-case assumption. A more constructive stance would require either a cheap price or evidence that zanzalintinib's launch trajectory meaningfully expands the earnings base beyond 2027.

Thesis delta

Thesis delta is minimal: the article confirms that zanzalintinib catalysts will occur by March 2027, slightly later than earlier expectations of a late-2026 PDUFA, but does not change probability of success or the commercial opportunity. The investment thesis remains a WAIT: Cabometyx's durability and zanzalintinib's optionality are already reflected in a 17x EPS multiple with limited margin of safety. We continue to target $38 as an attractive entry and $52 as a trim level, reassessing after FDA action and updated share-trend data.